SciLifeLab Group leader, Sara Mangsbo, Uppsala University, and her immunotherapeutic cancer vaccine delivery-platform, is now ready to leave the SciLifeLab Drug Discovery and Development platform (DDD).
The immunotherapeutic cancer vaccine delivery platform is based on a new technique, called Ada